Sildenafil Actavis

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

sildenafil

Disponibbli minn:

Actavis Group PTC ehf

Kodiċi ATC:

G04BE03

INN (Isem Internazzjonali):

sildenafil

Grupp terapewtiku:

Urologicals

Żona terapewtika:

Erectile Dysfunction

Indikazzjonijiet terapewtiċi:

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Sildenafil Actavis to be effective, sexual stimulation is required.

Sommarju tal-prodott:

Revision: 17

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2009-12-10

Fuljett ta 'informazzjoni

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SILDENAFIL ACTVIS 25 MG, 50 MG AND 100 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 25 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 50 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 100 MG FILM-COATED TABLETS
sildenafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or
nurse.This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sildenafil Actavis is and what it is used for
2.
What you need to know before you take Sildenafil Actavis
3.
How to take Sildenafil Actavis
4.
Possible side effects
5.
How to store Sildenafil Actavis
6.
Contents of the pack and other information
1.
WHAT SILDENAFIL ACTAVIS IS AND WHAT IT IS USED FOR
Sildenafil Actavis contains the active substance sildenafil which
belongs to a group of medicines
called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping
to relax the blood vessels in
your penis, allowing blood to flow into your penis when you get
sexually excited. Sildenafil Actavis
will only help you to get an erection if you are sexually stimulated.
Sildenafil Actavis is a treatment for adult men with erectile
dysfunction, sometimes known as
impotence. This is when a man cannot get, or keep a hard, erect penis
suitable for sexual activity.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE SILDENAFIL ACTAVIS
DO NOT TAKE SILDENAFIL ACTAVIS
-
If you are allergic to sildenafil or any of the other ingredients of
this medicine (listed in section
6).
-
If you are taking medicines called nitrates, as the combination may
lead to a dangerous fall in
your blood pressure
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sildenafil Actavis 25 mg film-coated tablets
Sildenafil Actavis 50 mg film-coated tablets
Sildenafil Actavis 100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains sildenafil citrate equivalent to 25, 50 or 100 mg
of sildenafil.
Excipient with known effect
Sildenafil Actavis 25 mg tablets
Each tablet contains 62.38 mg lactose (as monohydrate).
Sildenafil Actavis 50 mg tablets
Each tablet contains 124.76 mg lactose (as monohydrate).
Sildenafil Actavis 100 mg tablets
Each tablet contains 249.52 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Sildenafil Actavis 25 mg film-coated tablets
Sildenafil Actavis 25 mg film-coated tablets are blue elliptical,
biconvex, 10.0 x 5.0 mm and marked
“SL25” on one side.
Sildenafil Actavis 50 mg film-coated tablets
Sildenafil Actavis 50 mg film-coated tablets are blue elliptical,
biconvex, 13.0 x 6.5 mm and marked
“SL50” on one side.
Sildenafil Actavis 100 mg film-coated tablets
Sildenafil Actavis 100 mg film-coated tablets are blue elliptical,
biconvex, 17.0 x 8.5 mm and marked
“SL100” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Sildenafil Actavis is indicated in adult men with erectile
dysfunction, which is the inability to achieve
or maintain a penile erection sufficient for satisfactory sexual
performance.
In order for Sildenafil Actavis to be effective, sexual stimulation is
required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adults _
The recommended dose is 50 mg taken as needed approximately one hour
before sexual activity.
3
Based on efficacy and tolerability, the dose may be increased to 100
mg or decreased to 25 mg. The
maximum recommended dose is 100 mg. The maximum recommended dosing
frequency is once per
day. If Sildenafil Actavis is taken with food, the onset of activity
may be delayed compared to the
fasted state (see section 5.2)
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 13-11-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 11-05-2015
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 13-11-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 13-11-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 13-11-2023

Fittex twissijiet relatati ma 'dan il-prodott